MeMed Wins €3M EU Grant to Support Development of ImmunoXpert Protein Dx | GenomeWeb

NEW YORK(GenomeWeb) – Israeli biotech firm MeMed announced this week that it has won a €3 million ($3.3 million) grant from the European Commission's Horizon 2020 Small to Medium-Sized Enterprise program.

According to Founder and CEO Eran Eden, the company will use the funds to develop a point-of-care version of its proteomic test to distinguish between viral and bacterial infections and to support a clinical study investigating the test's usefulness in diagnosing elderly patients with lower respiratory tract infections (LRTIs).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.